Chugai Pharmaceutical achieved net sales of approximately 663.3 billion yen (up 14.7% YoY) for the second quarter (midterm) of the fiscal year ending December 2026, maintaining solid performance. Operating income also grew significantly to approximately 319.6 billion yen (+16.9%), and net profit has increased substantially, drawing attention to shareholder returns and future business development.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4519-20260724-02.pdf","jir_short_summary":"Chugai Pharmaceutical achieved net sales of approximately 663.3 billion yen (up 14.7% YoY) for the second quarter (midterm) of the fiscal year ending December 2026, maintaining solid performance. Operating income also grew significantly to approximately 319.6 billion yen (+16.9%), and net profit has increased substantially, drawing attention to shareholder returns and future business development.","jir_summary":"### Outlook and Impact on Shareholders\nChugai Pharmaceutical continues to promote innovative drug development and global expansion, with a forecast of steady performance for the full fiscal year 2026. Shareholder return measures such as dividend increases and share buybacks are under consideration, positioning the company as an attractive investment. Anticipated new drug approvals and clinical trial advancements are expected to further strengthen the revenue base.","jir_financial_highlights":"Net Sales: 66,330 million yen (YoY +14.7%)\nOperating Income: 31,960 million yen (YoY +16.9%)\nNet Profit: 23,170 million yen (YoY +23.2%)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #FinancialResults, #JapanStocks","jir_key_figures":"Net Sales: 66,330 million yen (up 14.7% YoY)\nOperating Income: 31,960 million yen (up 16.9% YoY)\nNet Profit: 23,170 million yen (up 23.2% YoY)","jir_meta_title":"\u3010Chugai Pharmaceutical\u30112026 Midterm Financial Results | Significant Increase in Revenue and Profit","jir_meta_description":"Chugai Pharmaceutical achieved solid performance in the second quarter of fiscal year 2026 with net sales of about 66.33 billion yen and operating profit of approximately 31.96 billion yen. Focus on future prospects and shareholder returns.","jir_og_title":"Chugai Pharmaceutical 2026 Midterm Financial Results | Steady Growth in Revenue and Profit","jir_og_description":"Chugai Pharmaceutical's second quarter results for FY 2026 show sales of 66.33 billion yen and operating income of 31.96 billion yen. Expectations for future growth and shareholder returns are high.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-12-31\\\",\\\"2026-03-31\\\",\\\"2026-06-30\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Revenue (Million Yen)\\\",\\\"data\\\":[5785,6633,\u4e0d\u660e],\\\"borderColor\\\":\\\"#36A2EB\\\",\\\"fill\\\":false}]} }\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-12-31\\\",\\\"2026-03-31\\\",\\\"2026-06-30\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (Million Yen)\\\",\\\"data\\\":[2733,3196,\u4e0d\u660e],\\\"borderColor\\\":\\\"#4BC0C0\\\",\\\"fill\\\":false}]} }\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-12-31\\\",\\\"2026-03-31\\\",\\\"2026-06-30\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (Million Yen)\\\",\\\"data\\\":[2317,2317,\u4e0d\u660e],\\\"borderColor\\\":\\\"#FF6384\\\",\\\"fill\\\":false}]} }\"}, {\"jir_chart_id\": \"research_development_spending\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Research and Development Spending Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-12-31\\\",\\\"2026-03-31\\\",\\\"2026-06-30\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses (Million Yen)\\\",\\\"data\\\":[863,902,\u4e0d\u660e],\\\"backgroundColor\\\":\\\"#FFCE56\\\"}]} }\"}, {\"jir_chart_id\": \"profit_margin\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Operating Profit Margin\\\",\\\"Net Profit Margin\\\"],\\\"datasets\\\":[{\\\"data\\\":[49.8,34.9],\\\"backgroundColor\\\":[\\\"#36A2EB\\\",\\\"#FF6384\\\"]}]}}\"}]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-88053","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n